Liabilities / Assets
83rd percentile
Higher debt load relative to assets than 83% of similar nonprofits.
990EZ • Fiscal year 2019 • EIN 81-2330581
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
Liabilities / Assets
83rd percentile
Higher debt load relative to assets than 83% of similar nonprofits.
Liabilities / Revenue
81st percentile
Higher debt load relative to revenue than 81% of similar nonprofits.
Net Margin
46th percentile
Higher net margin than 46% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
77th percentile
Faster asset growth than 77% of similar nonprofits.
Revenue Growth
14th percentile
Faster revenue growth than 14% of similar nonprofits.
Assets
Up$78,506
Up $17,493 (+29%) from 2018
Net Assets
-
No earlier filing loaded for comparison.
Liabilities
Up$14,400
Up $14,400 from 2018
Revenue
Down$195,886
Down $114,364 (-37%) from 2018
Expenses
Down$192,793
Down $82,397 (-30%) from 2018
Net Income
Down$3,093
Down $31,967 (-91%) from 2018
This 2019 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
The TARGIT Collaborative Group (TCG) is a cooperative effort between radiation oncologists, cancer surgeons, physicists and other experts in intraoperative radiotherapy that share a common mission to improve cancer patient care through education, patient advocacy, mentorship, and collaborative research.New technologies and innovations are enabling physicians to provide safe, effective, and less harmful treatments to patients. A major initial focus of the organization will be on increasing physician and patient awareness and access to targeted intraoperative radiotherapy, an innovative cancer treatment thatreduces the side effect and burden of cancer care.TARGit Intraoperative radioTherapy (TARGIT) is a type of accelerated radiation treatment that has been most commonly used in breast cancer to deliver a complete course of radiation to the cancer site during surgery, immediately following cancer removal. In most cases, this single treatment eliminates the need for the usual 4-6 week cou
No mirrored PDF or thumbnail assets are attached yet.
Displayed year
2019 • Form 990EZSummary only. Only limited summary data is available for this year.